Long noncoding RNAs in pulmonary airway inflammation
AssigneeThe Florida International University Board of Trustees
InventorsHitendra S. Chand, Madhavan Nair
Life of this patent
Estimating the term…
Abstract
The subject invention provides methods, assays, and products for preventing and/or treating pulmonary diseases. The present invention provides methods for identifying inhibitors of lncRNAs, pharmaceutical compositions comprising such inhibitors, and method of using said inhibitors in preventing and/or treating pulmonary airway inflammation. The present invention also develop novel strategies to modulate the mucous response for preventing, intervening, diagnosing and treating pulmonary airway inflammation, asthma, chronic obstructive pulmonary diseases (COPD) and Chronic mucus hypersecretion (CMH) pathogenesis.
Claims20
A pharmaceutical composition comprising one or more inhibitors of a long noncoding RNA (lncRNA) and a pharmaceutically acceptable carrier, the inhibitor comprising a siRNA selected from
- i) X1 siRNA (6-30):
- SEQ ID NOs:
- 4-5;
- ii) X2-A siRNA (26-55):
- SEQ ID NOs:
- 6-7;
- iii) X2-B siRNA (35-59):
- SEQ ID NOs:
- 8-9;
- and
- iv) X3 siRNA (37-61):
- SEQ ID NOs:
- 10-11.
Dependencies are inferred from the claim text.